FDA Blocks Imports and Prompts Recall of Sildenafil and Tadalafil Ingredients From an Indian Plant That Supplied U.S. Compounding Pharmacies

The U.S. Food and Drug Administration has cut off imports from an Indian company that supplied the raw active ingredients for compounded erectile dysfunction medications, and the firm has recalled the ingredients it already sent to U.S. compounding pharmacies. The action reaches into a supply chain that feeds a large share of the online men's health market, where compounded erectile dysfunction treatment is a staple telehealth product.

The FDA laid out the case against Shoolin Pharma Chem LLP in a warning letter dated August 18, 2026, which describes insanitary manufacturing conditions documented during a spring inspection of the company's plant in Gujarat, India. This article summarizes what the FDA found, what was recalled, and why it matters for patients who get ED medication online. It is general information, not medical advice.

What the FDA did

According to the FDA warning letter (reference 320-26-116), the agency placed all drugs and drug products offered for import from Shoolin Pharma Chem on Import Alert 66-40 on August 11, 2026. That designation lets the FDA detain the company's shipments at the border without first physically examining them, effectively halting its products from entering the country.

Separately, the FDA recommended a recall on July 27, 2026. On August 4, 2026 the company initiated what the FDA describes as a voluntary recall of all active pharmaceutical ingredients it had already distributed in the U.S. market. The August 18 warning letter formalized the agency's findings and gave the firm 15 business days to respond.

Which ingredients are involved

The warning letter states that Shoolin Pharma Chem manufactured active pharmaceutical ingredients that were imported into the United States and used by compounding pharmacies to produce medications for U.S. patients. The ingredients named include sildenafil citrate and tadalafil, both used for erectile dysfunction, along with an anticonvulsant ingredient and other products the FDA redacted from the public letter.

An active pharmaceutical ingredient, or API, is the raw chemical that gives a medication its effect. Compounding pharmacies buy bulk APIs and combine them into finished preparations. This action concerns the bulk ingredient supply from one firm. FDA-approved brand-name sildenafil (Viagra) and tadalafil (Cialis), and FDA-approved generics made from other manufacturers' ingredients, are not part of this recall.

What inspectors found

The FDA inspected the company's facility in Mehsana, Gujarat, from April 13 to 17, 2026. The warning letter cites a series of deviations from current good manufacturing practice (CGMP), the baseline quality standards drug ingredient makers must meet.

• Layered, unidentified residues and corroded equipment surfaces near open processing lines, and an employee observed wearing open-toed sandals in the production area directly in front of open equipment.
• Inadequate procedures for cleaning and maintaining manufacturing equipment.
• Incomplete laboratory testing records, with the firm unable to provide equipment printouts, laboratory notebooks, worksheets, and analytical data.
• Stability sample storage chambers found powered off and outside specification for temperature or humidity.
• A quality unit that failed to validate manufacturing operations, calibrate equipment, qualify contract laboratories, and perform annual product reviews.

The FDA's warning letter reflects the agency's findings from the inspection. A warning letter is a formal notice of alleged violations, not a final court judgment, and it gives the company an opportunity to respond and remediate.

Why this matters for telehealth ED patients

Compounded sildenafil and tadalafil, often sold as chewable tablets, troches, or combination products, are among the most heavily marketed offerings in online men's health. Many telehealth platforms prescribe these compounded versions and route fulfillment through compounding pharmacies rather than retail pharmacies that dispense FDA-approved pills.

Because compounding pharmacies source bulk APIs from suppliers like Shoolin Pharma Chem, a quality problem at the ingredient level can affect finished products regardless of which telehealth brand sold them. The FDA has not named specific compounding pharmacies or telehealth companies that received the recalled ingredients, and the agency has not reported confirmed patient harm tied to this recall. The action is a manufacturing and quality enforcement step, not a finding that any specific dose injured a patient.

How compounded ED drugs differ from approved pills

FDA-approved sildenafil and tadalafil, both brand and generic, are made under inspected manufacturing and tested batch by batch before sale. Compounded versions are not FDA-approved as individual products; they are prepared by pharmacies and depend heavily on the quality of the ingredients and the pharmacy's own practices. The FDA permits compounding in defined circumstances, but it has repeatedly cautioned that compounded drugs carry different risks than approved products.

What patients can do

Patients who take compounded ED medication and have questions should talk with the prescribing clinician or the dispensing pharmacy about where the ingredients were sourced and whether their product is affected. Anyone who experiences a problem with a medication can report it to the FDA's MedWatch program. This is general information and not medical advice; decisions about stopping or continuing any prescription should be made with a licensed clinician.